MedPath

Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Phase 1
Completed
Conditions
Hidradenitis Suppurativa
Interventions
Registration Number
NCT04989517
Lead Sponsor
Azora Therapeutics Australia Pty Ltd
Brief Summary

This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
49
Inclusion Criteria
  • Diagnosis of HS or signs and symptoms consistent with HS for at least 3 months before screening in the judgment of the investigator.
  • Stable disease for at least 2 months before screening in the judgment of the investigator.
  • A woman of childbearing potential must use appropriate contraceptive measures during the study period.
  • A woman of childbearing potential must have a negative urine pregnancy test result at screening.
  • Written informed consent must be obtained before any study procedure is performed.
Exclusion Criteria
  • Pregnant or breastfeeding.
  • Any active skin disease that may interfere with evaluation of study drug or outcome assessment.
  • History or evidence of a clinically significant disorder, condition, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion in the judgment of the investigator.
  • Change in smoking or marijuana history within 3 months before Day 1 or planned during study period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboAT193Topical applied daily
AT193AT193Topical applied daily
Primary Outcome Measures
NameTimeMethod
Incidence of treatment-emergent adverse events10 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (7)

Premier Specialists

🇦🇺

Kogarah, New South Wales, Australia

Holdsworth House Medical Practice

🇦🇺

Darlinghurst, New South Wales, Australia

East Sydney Doctors

🇦🇺

Darlinghurst, New South Wales, Australia

Veracity Clinical Research

🇦🇺

Woolloongabba, Queensland, Australia

Novatrials

🇦🇺

Kotara, New South Wales, Australia

North Eastern Health Specialists

🇦🇺

Campbelltown, South Australia, Australia

Woden Dermatology

🇦🇺

Phillip, Australian Capital Territory, Australia

© Copyright 2025. All Rights Reserved by MedPath